Ruiyang Liu

Ruiyang Liu

Auto-generated profile, based on publicly available information

Ruiyang Liu

Department of Medicine, Washington University in St. Louis, St. Louis, Missouri

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
LYLijun Yao
Lijun Yao
JWJulia T. Wang
Julia T. Wang
RJReyka G. Jayasinghe
Reyka G. Jayasinghe
JOJulie O'NEal
Julie O'NEal
CTChia-Feng Tsai
Chia-Feng Tsai
JDJohn F DiPersio
John F DiPersio
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy. Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.

27 September 2023 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYige Wu
Yige Wu
SCSiqi Chen
Siqi Chen
XYXiaolu Yang
Xiaolu Yang
KSKazuhito Sato
Kazuhito Sato
PLPreet Lal
Preet Lal
FCFeng Chen
Feng Chen
Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial–mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs.Significance: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors.

13 December 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
QDQingmiao Ding
Qingmiao Ding
YGYuning Gao
Yuning Gao
RLRuiyang Liu
Ruiyang Liu
YLYaozhi Li
Yaozhi Li
Lei JinLei Jin
Lei Jin
HMHan Ma
Han Ma
The influence of direct current interference on the corrosion behavior of HRB400 and HRB400M steel bars in simulated concrete solution was studied using methods such as weight loss experiment, electrochemical experiment, surface technology and product analysis. The research results showed that with the increase of DC interference voltage, the corrosion rates of HRB400 and HRB400M steel bars would increase. The corrosion resistance of HRB400M steel bars was better than HRB400 steel bars under the experimental conditions. In addition, direct current interference could cause damage to the corrosion product layer on the surface of HRB400 steel bars and HRB400M steel bars. And the corrosion form and corrosion product types of HRB400 and HRB400M steel bars would be affected by direct current interference. The main corrosion products of HRB400 steel bars included γ-FeOOH and Fe2O3 when it was not interfered by DC. When DC interference was applied, the main corrosion products included Fe3O4 and Fe2O3. The corrosion products on the surface of HRB400M steel bars were mainly Fe3O4 and Fe2O3, and the types of products increased to form Cr2O3 and MnFe2O4.

14 April 2023
Verified
Other
Open access
LYLijun Yao
Lijun Yao
JWJulia T. Wang
Julia T. Wang
RJReyka G. Jayasinghe
Reyka G. Jayasinghe
JOJulie O'Neal
Julie O'Neal
CTChia-Feng Tsai
Chia-Feng Tsai
JDJohn F DiPersio
John F DiPersio
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.


14 April 2023
Verified
Other
Open access
LYLijun Yao
Lijun Yao
JWJulia T. Wang
Julia T. Wang
RJReyka G. Jayasinghe
Reyka G. Jayasinghe
JOJulie O'Neal
Julie O'Neal
CTChia-Feng Tsai
Chia-Feng Tsai
JDJohn F DiPersio
John F DiPersio
List of recurrent mutations with potential utility as neoantigens